Clinical trial · Observational
Analyses of Human Samples Collected in Clinical Trials
Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
NCT00339664CI-TRIAL-00044344completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes. The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphoid | Lymphoid Leukemia | ONTOLOGY_EXACT | 0.98 |
| Leukemia, Myeloid | Myeloid Leukemia | ALIAS | 0.90 |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- 1/ patients
- description
- Patients on approved clinical trials
Primary outcomes (1)
- measure
- Drug and/or metabolite concentration
- timeFrame
- Ongoing
- description
- To quantitate drug and/or metabolite concentrations in human blood samples
Secondary outcomes (1)
- measure
- Pharmacological behavior of agents
- timeFrame
- Ongoing
- description
- To characterize the clinical pharmacological behavior of agents
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 100 Years
Show eligibility criteria text
* INCLUSION CRITERIA: Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer at institutions outside of the intramural NCI are eligible for inclusion, provided that they have consented to pharmacological analysis in the original consent form. EXCLUSION CRITERIA: None anticipated at this time.
References
Publications (0)
Data not yet available
No reference posted for this study.